

**Subjective and Objective Performance of Systane Complete Multi-Dose
PF versus Walgreen's Lubricant Balance**
An investigator-initiated clinical trial

1. TITLE PAGE

Protocol Number:	JM-23-02
Amendment Number	Version 1.0
IRB / ERC	Salus IRB 2111 West Braker Lane, Suite 400 Austin, Texas 78758
Sponsor Name & Address:	Jay Mashouf, OD Scripps Optometric Group 10549 Scripps Poway Pkwy Ste G San Diego, CA 92131 <i>(funding only, this is an investigator-initiated study IIT # 89908509)</i> Alcon 6201 South Freeway, Fort Worth, TX 76134-2099, USA
Test Articles:	Systane Complete Multi-Dose PF Walgreen's Lubricant Balance
Investigator:	Jay Mashouf, OD

2 . INVESTIGATOR AGREEMENT

I confirm that I have read and that I understand this protocol entitled “Subjective and Objective Performance of Systane Complete Multi-Dose PF versus Walgreen’s Lubricant Balance”, and understand the use of the study products. I agree to conduct this study in accordance with the requirements of this protocol and also protect the rights, safety, privacy, and well-being of study subjects in accordance with the following:

- The ethical principles that have their origin in the Declaration of Helsinki.
- All applicable laws and regulations, including, without limitation, data privacy laws and regulations.
- Regulatory requirements for reporting serious adverse events defined in Section 13 of this protocol.s

Signature of Investigator (Date)

Investigator Name (print or type)

Investigator’s Title

Name of Facility

Location of Facility (City)

3. GENERAL INFORMATION

Objective	<p>To compare dry eye symptoms as well as corneal and conjunctival staining of Systane Complete Multi-Dose PF, versus the Walgreen's Lubricant Balance eye drop.</p> <p>The hypothesis is that mild to moderate dry eye subjects will exhibit less frequent and severe dry eye symptoms after using Systane Complete Multi-Dose PF versus those who use Walgreen's Lubricant Balance.</p>
Test Article(s)	Systane Complete Multi-Dose PF Walgreen's Lubricant Balance
Sample size	70 subjects
Study Population	Subjects who currently have mild to moderate symptoms of dry eye.
Number of sites	One
Study Design	Single site, prospective, double-masked, randomized-controlled study with two arms
Masking	Double-masked
Variables	<p>Primary: Dry eye symptom frequency and severity as measured by the SANDE questionnaire change after 2 weeks of QID use.</p> <p>Exploratory:</p> <ul style="list-style-type: none">• Comparing corneal and conjunctival staining before and after 2 weeks of QID use of their assigned drop.• Comparing Non-invasive TBUT times of the subjects in the two arms of the study, before and after 2 weeks of QID use of their assigned drop.• Dry eye symptom frequency and severity as measured by the SANDE questionnaire after 1 week of QID use.
Duration / Follow-up	Screening Visit to 2 weeks follow-up

The study will be registered with clinicaltrials.gov.

The study will be conducted in compliance with the protocol, GCP and applicable regulatory requirements

4. TABLE OF CONTENTS

1. TITLE PAGE.....	1
2 . INVESTIGATOR AGREEMENT	2
3. GENERAL INFORMATION.....	3
4. TABLE OF CONTENTS	4
5. INTRODUCTION	6
6. OBJECTIVE(S)	6
7. SUBJECTS	6
7.1. Subject Population	6
7.2. Inclusion Criteria	6
7.3. Exclusion Criteria.....	7
8. STUDY DESIGN	7
8.1. Study Design.....	7
8.2. Methods Used to Minimize Bias.....	8
8.3. Method of Assigning Subjects to Treatment Arms.....	8
9. STUDY PROCEDURE	8
9.1. Informed Consent / Subject enrollment	8
9.2. Visits and Examinations.....	8
9.3. Study Methods and Measurements.....	10
9.4. Unscheduled Visits	11
9.5. Discontinued Subjects	11
10. ANALYSIS PLAN.....	11
10.1. Analysis Data Sets.....	11
10.2. Statistical Methodology	11
10.3. General Statistical Considerations	12
11. SAMPLE SIZE JUSTIFICATION	12
12. CONFIDENTIALITY/PUBLICATION OF THE STUDY	12
13. QUALITY COMPLAINTS AND ADVERSE EVENTS	13
13.1. General Information.....	13
13.2. Monitoring for Adverse Events	13
13.3. Procedures for Recording and Reporting AEs and SAEs.....	13

13.4. Follow-Up of Adverse Events and Quality Complaints	16
13.5. Safety Analyses.....	16
14. GCP, ICH and ETHICAL CONSIDERATIONS	16
14.1 Confidentiality	16
15. STANDARD EVALUATION PROCEDURES	18
Table 15.1. Proposed Visits and Study Assessments.....	18
16. CONFIDENTIALITY	18
17. FINANCIAL AND INSURANCE INFORMATION/STUDY RELATED INJURIES.....	18
18. STUDY ENDPOINT CRITERIA	19
18.1. Patient Completion of Study	19
18.2. Patient Discontinuation.....	19
18.3. Patient Termination	19
18.4. Study Termination.....	19
18.5. Study Completion.....	19
19. SUMMARY OF RISKS AND BENEFITS.....	19
19.1. Summary of risks	19
19.2. Summary of benefits	19
REFERENCES	20

5. INTRODUCTION

There are a vast array of lubricating eyedrops available on the market that can confuse and frustrate consumers. Many consumers view these the various products as “all the same” and often do not base their purchase on science or their doctor’s recommendation, but a variety of other factors including cost, store merchandising, and a potential view that all products are the same.

However, even products that list the same active ingredient can have vastly different inactive ingredients resulting in a potentially different outcome for the patient. For example, Walgreen’s Lubricant Balance eyedrop and Alcon’s Systane Complete Multi-Dose Preservative Free (PF) eyedrop has the same active ingredient (0.6% propylene glycol), however, Walgreen’s Lubricant Balance eyedrop is preserved in benzalkonium chloride (BAK), a known cause of ocular dryness and corneal and conjunctival staining.¹ To date, there is little data comparing the clinical outcomes between these two eyedrops.

The purpose of this study is to compare dry eye symptoms as well as corneal and conjunctival staining of Systane Complete Multi-Dose PF, versus the Walgreen’s Lubricant Balance eye drop.

6. OBJECTIVE(S)

To compare dry eye symptoms as well as corneal and conjunctival staining of Systane Complete Multi-Dose PF, versus the Walgreen’s Lubricant Balance eye drop.

7. SUBJECTS

7.1. Subject Population

Eligible test subjects will be 18-45 years of age who currently have mild to moderate symptoms of dry eye as defined by a screening SANDE score of 20 to 55 inclusive (equivalent to OSDI score of 12 to 32).²

A total of 70 subjects at one site will be enrolled. Both eyes of a subject must be enrolled. Subjects must meet the inclusion criteria. Prior to enrollment, subjects will be provided information on the study and asked to sign a patient information and consent form to participate. The patient information and consent form will be approved by an appropriate ethics committee.

7.2. Inclusion Criteria

Subjects are eligible for the study if they meet the following criteria:

Note: Ocular criteria must be met in both eyes.

- Subjects who currently have mild to moderate symptoms of dry eye as defined by a screening SANDE score of 20-55 inclusive (equivalent to OSDI score of 12 - 32).²
- Subjects between the ages of 18-65.

- Subjects willing to comply with the prescribed regimen and schedule of eye drops.
- Subjects willing to attend all study visits.
- Subjects willing to discontinue any current artificial tear use 24 hours prior to the baseline study visit.

7.3. Exclusion Criteria

If any of the following exclusion criteria are applicable to the subject or either eye, the subject should not be enrolled in the study.

- Ocular anterior segment infection, inflammation, abnormality, or active disease.
- History of herpetic keratitis or ocular surgery.
- Recent (within 1 year) thermal meibomian gland expression procedure including Lipiflow, iLux, or TearCare.
- Recent (within 1 year) blepharitis debridement procedure including BlephEx.
- Screening SANDE score > 55 (equivalent to OSDI score of >32).² This is indicative of a severe dry eye.
- Screening SANDE score < 20 (equivalent to OSDI score of <12).² This is indicative of a clinically normal eye.
- Screening non-invasive TBUT < 2 seconds, or > 10 seconds.³
- Screening NaFl score < 3 (clinically normal eye) or > 10 (severe dry eye).⁴
- Pregnant or lactating.
- Current use of contact lenses.
- Any change in eye drop regimen, whether OTC or RX in the last 90 days.

The principal investigator reserves the right to declare a patient ineligible or non-evaluable based on medical evidence that indicates they are unsuitable for the trial.

Pregnancy has a known effect on the stability of refractions and visual acuity. As such, subjects who become pregnant during the study will not be discontinued but their data may be excluded from analyses of effectiveness.

8. STUDY DESIGN

8.1. Study Design

Single site, prospective, double-masked, randomized-controlled, two-arm study of the dry eye symptoms as well as corneal and conjunctival staining in subjects using 2 different eyedrops. Subjects will be assessed at a screening visit, and 2 follow-up visits. Clinical evaluations will include patient questionnaire, tear-breakup time, and slit lamp exam.

The primary outcome measure is Dry eye symptom frequency and severity as measured by the SANDE questionnaire change after 2 weeks of QID use.

Exploratory outcome measures are as follows:

- Comparing corneal and conjunctival staining before and after 2 weeks of QID use of their assigned drop.
- Comparing Non-invasive TBUT times of the subjects in the two arms of the study, before and after 2 weeks of QID use of their assigned drop.
- Dry eye symptom frequency and severity as measured by the SANDE questionnaire after 1 week of QID use.

8.2. Methods Used to Minimize Bias

Patient selection will be based on the patient's interest and the optometrist's opinion as to whether they are a suitable candidate for eyedrops. Subjects will be randomized to treatment groups.

All data collection will be completed through provided Case Report Forms (CRFs) or computer files generated by automated test equipment. All site personnel involved in the study will be trained in regard to conducting study-specific procedures.

8.3. Method of Assigning Subjects to Treatment Arms

Subjects will be assigned to Systane Complete Multi-Dose PF or the Walgreen's Lubricant Balance treatment groups in a 1:1 ratio using the method of randomly permuted blocks.

9. STUDY PROCEDURE

9.1. Informed Consent / Subject enrollment

No subject will be enrolled into the study who does not meet the inclusion/exclusion criteria and does not sign the current approved informed consent document. Informed consent will be obtained prior to collecting any data for the study. The original signed documents will be maintained by the investigator as a permanent part of the subject's medical records. A signed copy will be provided to the subject.

9.2. Visits and Examinations

Subjects will participate in 3 study visits. Visits will include an uptake visit and 2 follow up visits (Visit numbers 1-3 below). The visit schedule, complete with window and associated CRF forms, are displayed in Table 9.2-1. Details of each study visit, including testing to be conducted, are provided below.

Table 9.2-1. Visit Schedule

Visit Number	Visit Name	Visit Window	CRF Number
1	Recruitment	Day 0	1
2	Follow-Up Visit 1	Day 7 \pm 1 day	2
3	Follow-Up Visit 2	Day 14 \pm 2 days	3

9.2.1. Recruitment

At the recruitment visit, subjects will be consented, qualified for the study (compared with inclusion/exclusion criteria), and assigned a study ID/subject number. Subject numbers will be assigned sequentially at each site in the order of enrollment.

A medical history will be taken and exams will include the tests described below:

- slit lamp exam including evaluation of staining,
- non-invasive tear breakup time,
- SANDE questionnaire.

In addition, all site-specific, routine, usual standard of care measures should be undertaken.

Measurements should be made as described in section 9.3 below.

9.2.2. Follow-Up Visit 1

Exams will include the tests described below:

- SANDE questionnaire,
- compliance check.

In addition, all site-specific, routine, usual standard of care measures should be undertaken.

Any adverse events/serious adverse events (AEs/ SAEs) occurring during surgery will be noted at this visit. Any other problems during surgery and comments regarding surgery will be documented.

9.2.3. Follow-Up Visit 2

Exams will include the tests described below:

- slit lamp exam including evaluation of staining,
- non-invasive tear breakup time,

- SANDE questionnaire,
- compliance check.

In addition, all site-specific, routine, usual standard of care measures should be undertaken.

Any adverse events/serious adverse events (AEs/ SAEs) occurring during surgery will be noted at this visit. Any other problems during surgery and comments regarding surgery will be documented.

9.2.4. Exit Procedures

In the event of premature exit from the study, all study related examinations should be completed where possible. The Exit CRF should be completed, noting that the subject did not complete the study and the reason for premature study exit. If no premature exit from the study occurs, the Exit CRF should be completed at the end of Visit 3.

9.3. Study Methods and Measurements

All routine testing and basic eye examinations should be carried out at each study visit. Abnormalities should be recorded in the CRF “Comment” section. Specific study examination procedures are outlined below.

9.3.1. Non-Invasive Tear Breakup Time

Non-invasive TBUT determined using the Topcon CA-800. Subject will be instructed to blink 3 times and then hold eye open without blinking while test is being performed. Three (3) consecutive readings will be taken, and the average will be recorded in seconds. The Topcon CA-800 measuring is not able to be customized via software settings so the factory setting will be used. Both eyes will be tested, but for the purposes of this study only a single, randomly selected eye will be used for statistical analysis.

9.3.2. Staining

Baseline corneal and conjunctival staining with sodium fluorescein and Wratten filter assessed OU using the Academy of Ophthalmology 5 quadrant scheme. Each quadrant will be graded (0-3) giving a total score of 0-15 per eye. Again, both eyes will be evaluated, but only the total score of the single, previously selected eye in the TBUT measurement will be used for statistical analysis.

9.3.3 Questionnaires

The SANDE questionnaire, will be administered to subjects at all visits. The administrator should ensure the subjects understand the nature of the questions but should not interpret them for the subject.

9.4. Unscheduled Visits

Unscheduled exams may be conducted at the discretion of the Investigator with all relevant information from the exam recorded in the source documents and on the Unscheduled Visit pages within the CRF booklet.

9.5. Discontinued Subjects

Discontinued subjects are those who do not have an exit visit or who come into the office to be exited prior to the scheduled final study visit. Subjects may be discontinued from the study at any time if, in the opinion of the investigator, their continued participation in the study poses a risk to their health. The reasons for discontinuation include:

- a. Adverse event;
- b. Lost to follow-up;
- c. Subject decision unrelated to an adverse event;
- d. Protocol violation;
- e. Treatment failure;
- f. Other.

To ensure the safety of all subjects who discontinue prior to Visit 3, investigators should assess each subject and, if necessary, advise them of any therapies and/or medical procedures that might be needed to maintain their health. Any changes in medical health and/or use of concomitant medications should also be captured.

10. ANALYSIS PLAN

10.1. Analysis Data Sets

All subjects who are enrolled in the study will be evaluated for safety. Efficacy analyses will be performed based on data from those eyes that complete the study.

10.2. Statistical Methodology

Analysis will be done on the per protocol population. For monocular outcomes, analysis will be performed on the study eye that was determined by randomization.

Superiority of Systane COMPLETE relative to Walgreens will be established if the mean SANDE score is significantly lower in the Systane COMPLETE group vs. Walgreens group.

Demographics, baseline characteristics, efficacy endpoints, and adverse events will be summarized descriptively. Summaries of these variables will include sample size, as well as the mean, median, standard deviation, minimum and maximum.

Primary Endpoint: Dry eye symptom frequency and severity as measured by the SANDE questionnaire change after 2 weeks of QID use (subject level). Total scores will be compared using a two-sample t-test.

The step-down methodology will be used on the other endpoints in the following order:

- Comparing corneal and conjunctival staining in the study eye before and after 2 weeks of QID use of their assigned drop (eye level). The corneal and conjunctival staining scores will be totaled from the 5 evaluation zones for analysis. Total scores will be compared using a two-sample t-test.
- Comparing Non-invasive TBUT times of the study eye in the two arms of the study, before and after 2 weeks of QID use of their assigned drop (eye level). Time will be compared using a two-sample t-test.
- Dry eye symptom frequency and severity as measured by the SANDE questionnaire after 1 week of QID use (subject level). Total scores will be compared using a two-sample t-test.

10.3. General Statistical Considerations

The statistical analyses will be performed using R, version 4.2.2 or higher. Any statistical tests of hypotheses will employ a level of significance of $\alpha=0.05$.

11. SAMPLE SIZE JUSTIFICATION

Assuming a difference in means between groups of 7 (SANDE) and a pooled standard deviation of 6, the study would require a sample size of 16 subjects for each group (total sample size of 32 subjects) to achieve a power of 90% and a level significance of 5%. To increase the study power and account for dropout, the sample size is being increased to 70 subjects (35 in each arm) to thoroughly characterize the performance of the drops.

12. CONFIDENTIALITY/PUBLICATION OF THE STUDY

The existence of this Study is confidential and should not be discussed with persons outside of the Study. Results will be submitted for publication and presentation at national and/or international meetings. A manuscript will be submitted to peer-review journals for publication but there is no guarantee of acceptance.

All study data will be collected on appropriate Case Report Forms (CRFs). No protected health information will be included on the forms. CRFs will be retained in the patient's file for a minimum period of 3 years. Collected information will only be used for purposes of this study and no information will be sold to third parties. The following people will have access to your study records:

- Study Doctor and staff involved with the study
- Study Monitor or Auditor
- Sponsor Company or Research Institution
- Review boards or accrediting agencies
- Other State or Federal Regulatory Agencies

The de-identified data may be shared with other researchers for future analysis.

13. QUALITY COMPLAINTS AND ADVERSE EVENTS

All subjects will be monitored for adverse events over the course of the study. A place to record any adverse event is included on each case report form.

13.1. General Information

An Adverse Event (AE) is any untoward medical occurrence in a subject who is administered a study treatment regardless of whether or not the event has a causal relationship with the treatment. An AE, therefore, can be any unfavorable or unintended sign (including an abnormal laboratory finding), symptom, or disease temporally associated with the study treatment, whether or not related to the treatment. In clinical studies, an AE can include an untoward medical occurrence occurring at any time, including run-in or washout periods, even if no study treatment has been administered.

13.2. Monitoring for Adverse Events

At each visit, after the subject has had the opportunity to spontaneously mention any problems, the Investigator should inquire about AEs by asking if the patient has any problems.

13.3. Procedures for Recording and Reporting AEs and SAEs

Subsequent to signing an informed consent form, all untoward medical occurrences that occur during the course of the study must be documented on an Adverse Event Form (AEF). A separate AEF must be filled out for each event. When possible, signs and symptoms indicating a common underlying pathology should be documented as one comprehensive event. For each recorded event, the AE documentation must include the onset date, outcome, resolution date (if event is resolved), intensity (i.e., severity), any action with study treatment taken as a result of the event, and an assessment of the adverse event's relationship to the study treatment.

Nonserious Adverse Events

A nonserious AE is defined as any untoward change in a subject's medical health that does not meet serious criteria noted below (e.g., is not life-threatening, does not require hospitalization, does not prolong a current hospitalization, is not disabling, etc.). All adverse events must be reported regardless of whether or not they are related to the study treatment.

For nonserious adverse events, an AEF containing all available information will be collected on a routine basis and submitted to the Medical Monitor at the close of the study.

Serious Adverse Events

A serious adverse event (SAE) is defined as any adverse experience that meets any of the following criteria:

- Results in death.
- Is life-threatening.

- NOTE: Life-threatening means that the subject was at immediate risk of death from the reaction as it occurred; i.e., it does not include a reaction which hypothetically might have caused death had it occurred in a more severe form.
- Requires inpatient hospitalization or prolongation of existing hospitalization.
NOTE: In general, hospitalization signifies that the individual remained at the hospital or emergency ward for observation and/or treatment (usually involving an overnight stay) that would not have been appropriate in the physician's office or an out-patient setting. Complications that occur during hospitalization are AEs. If a complication prolongs hospitalization or fulfills any other serious criteria, the event is serious. When in doubt as to whether "hospitalization" occurred, the event should be considered serious.
 - Results in persistent or significant disability/incapacity. Disability is defined as a substantial disruption of a person's ability to conduct normal life functions.
NOTE: The term disability means a substantial disruption of a person's ability to conduct normal life functions. This definition is not intended to include experiences of relatively minor medical significance such as uncomplicated headache, nausea, vomiting, diarrhea, influenza, or accidental trauma (e.g., sprained ankle) which may interfere or prevent everyday life functions but do not constitute a substantial disruption.
 - Is an important medical event. An important medical event is an event that may not result in death, be life-threatening, or require hospitalization but may be considered an SAE when, based upon appropriate medical judgment, it may jeopardize the subject and may require medical or surgical intervention to prevent one of the outcomes listed in the definitions for SAEs. Examples of such medical events include allergic bronchospasm requiring intensive treatment in an emergency room or at home, blood dyscrasias or convulsions that do not result in subject hospitalization, or the development of drug dependency or drug abuse.
All available information on a serious adverse event(s) and any other associated AE, if applicable, must be forwarded to the study coordinator for forwarding to the Medical Monitor immediately (i.e., within one working day of the Investigator's or site's knowledge of the event) as follows:
 - In studies utilizing EDC (electronic data capture), all available information for the SAE and any associated AE(s) must be entered immediately into the EDC system.
 - Additional information for any applicable event is to be reported as soon as it becomes available.

In addition to the reporting of serious adverse events to the study Medical Monitor, the SAE must be reported to the IRB / IEC according to their requirements.

The investigator must document all adverse device events (serious and nonserious but related) and all serious adverse events (related and unrelated) on the Adverse Device Effect and Serious Adverse Event Form. Any device quality complaints will also be documented.

- **Both the Quality Complaint Form and the Adverse Device Effect and Serious Adverse Event Form must be e-mailed immediately to the study coordinator.**
- **Additional relevant information is to be reported as soon as it becomes available.**

Study coordinator contact information is provided below.

**Table 13.3.-1:
Contact Information for Study**

Study Staff	Business Phone	e-mail	24-hour Office Phone
Leslie Shan	858-530-2800	lshanod@gmail.com	858-530-2800

Further, depending upon the nature of the adverse event (serious or nonserious) or quality complaint being reported, the study sponsor may request copies of applicable portions of the subject's medical records. The investigator must also report all adverse events and quality complaints according to the relevant IRB requirements.

12.3.1 Intensity and Causality Assessments

For every adverse event and quality complaint, the investigator must assess the causality as Related or Not Related to the medical device under investigation. An assessment of causality will also be performed by the Medical Monitor utilizing the same definitions, as shown below:

Causality

- | | |
|--------------------|--|
| Related | An adverse event or quality complaint classified as related may be either definitely related or possibly related where a direct cause and effect relationship with the medical device has not been demonstrated, but there is a reasonable possibility that the adverse event or quality complaint was caused by the medical device. |
| Not Related | An adverse event or quality complaint classified as not related may either be definitely unrelated or simply unlikely to be related (i.e., there are other more likely causes for the adverse event or quality complaint). |

Where appropriate, the investigator must assess the intensity (severity) of the adverse event as mild, moderate, or severe based on medical judgment with consideration of any subjective symptom(s), as defined below:

Intensity (Severity)

Mild	An adverse event is mild if the subject is aware of but can easily tolerate the sign or symptom.
Moderate	An adverse event is moderate if the sign or symptom results in discomfort significant enough to cause interference with the subject's usual activities.
Severe	An adverse event is severe if the sign or symptom is incapacitating and results in the subject's inability to work or engage in their usual activities.

The investigator must document any action taken (i.e., medication, intervention, or treatment plan) and outcome of the adverse event or quality complaint when applicable.

13.4. Follow-Up of Adverse Events and Quality Complaints

The investigator is responsible for adequate and safe medical care of subjects during the study and for ensuring that appropriate medical care and relevant follow-up procedures are maintained after the study. Any additional data from these follow-up procedures must be documented and available to the study coordinator who, with the Medical Monitor, will determine when the data need to be documented on the CRFs.

13.5. Safety Analyses

The type, severity, duration, and frequency of reported ocular adverse events will be tabulated. Adverse events will also be summarized for events that were considered treatment-related.

14. GCP, ICH and ETHICAL CONSIDERATIONS

This study will be conducted in compliance with Good Clinical Practices (GCPs), including International Harmonization (ICH) Guidelines, and in general, consistent with the 1996 version of the Declaration of Helsinki. In addition, all applicable local, state and federal requirements will be adhered to.

This study is to be conducted in accordance with Institutional Review Board regulations. The investigator will obtain appropriate IRB/ethics committee approval prior to initiating the study.

The study will be registered with clinicaltrials.gov.

14.1 Confidentiality

The data collected will be data typical for the procedure(s) when performed on eyes outside the study. Any data collected will become part of the patient's clinical record. The data will be subject to the same privacy and confidentiality as other data in the clinical record.

Only the principal investigator, research consultant and clinic staff will have access to the data collected. All data shared outside the practice will be de-identified; patients' protected health information will not be available and will not be reported in any analyses or publications. No data will be sold to third parties. De-identified data may be used for future research.

15. STANDARD EVALUATION PROCEDURES

Table 15.1. Proposed Visits and Study Assessments

(visits are by patient, with both eyes tested)

Activity	Recruit- ment	Follow-Up	Follow-Up
	Visit 1	Visit 2	Visit 3
Informed Consent	X		
Demographics	X		
General Information: Medical History	X		
Non-Invasive Tear Breakup Time	X		X
Slit Lamp Exam and Staining Evaluation	X		X
SANDE Questionnaire	X	X	X
Compliance Check		X	X
Monitor for Adverse Events		X	X
Complete Exit Form ¹			X

¹ Complete Exit Form upon termination of subject participation, or at Visit 3, whichever occurs first.

16. CONFIDENTIALITY

No protected health information (PHI), including the patient's name and date of birth, will be collected; to ensure this, no PHI information is permitted to be entered on any of the Case Report Forms (CRFs). Subjects will only be identified by subject IDs and identities will be removed at the initial visit so that there is no further need to protect or destroy the information. Collected information will only be used for purposes of this study and no information will be sold to third parties. The non-PHI information collected may be used for future research, though there is currently no plan to do so.

17. FINANCIAL AND INSURANCE INFORMATION/STUDY RELATED INJURIES

Every effort to prevent study-related injury will be taken by the Study Doctor and staff. In the event a patient is injured as a direct result of the study while following the Study Doctor's instructions and the study requirements, the patient will be instructed to contact his or her doctor immediately. The Study Doctor is to treat the injured subject as needed for those injuries caused directly by this research study. In the event of injury or illness caused by or occurring during a subject's participation in this research study, all charges for medical care provided to the subject will be billed to his or her insurance company. The Study Doctor or Sponsor does not offer to cover the medical care costs for injuries or illnesses that are not caused directly by the research study. The Sponsor does not offer to provide any other compensation, unless specifically agreed to elsewhere in this document. This information will be provided to each study subject before the start of the study in the consent form.

18. STUDY ENDPOINT CRITERIA

18.1. Patient Completion of Study

If a study patient has completed the final visit (Visit 3) of the study, he/she is considered to have completed the study.

18.2. Patient Discontinuation

Each study patient may voluntarily discontinue the study at any time they choose. Study patients who cannot complete the study for administrative reasons (e.g., non-compliance, failure to meet visit schedule, etc.) will be discontinued from the study. Study patients discontinued during the enrollment phase (prior to surgery) of the study will be replaced.

18.3. Patient Termination

A study patient will be terminated if the study patient develops any severe adverse event that may be related to the study. A study patient will receive appropriate treatment at the discretion of the investigator. Notification of termination will be clearly documented. These study patients are considered to have completed the study and will not be replaced.

18.4. Study Termination

The investigator with appropriate notification may terminate the study. If, after clinical observations, the investigator feels that it may be unwise to continue the study, he may stop the study.

18.5. Study Completion

The study will be complete when all enrolled patients have completed Visit 3 or have been terminated from the study.

19. SUMMARY OF RISKS AND BENEFITS

19.1. Summary of risks

The risks with this study are similar to those for any patient using lubricating drops. There is no increased risk associated with the proposed study.

19.2. Summary of benefits

Patients who participate in the study may receive up to \$75 reimbursement.

REFERENCES

1. Goldstein MH, Silva FQ, Blender N, Tran T, Vantipalli S. Ocular benzalkonium chloride exposure: problems and solutions. *Eye (Lond)*. 2022;36(2):361-368.
2. Amparo F, Schaumberg DA, Dana R. Comparison of Two Questionnaires for Dry Eye Symptom Assessment: The Ocular Surface Disease Index and the Symptom Assessment in Dry Eye. *Ophthalmology*. 2015;122(7):1498-1503.
3. Yazdani M, Fiskadal J, Chen X, et al. Tear Film Break-Up Time and Dry Eye Disease Severity in a Large Norwegian Cohort. *J Clin Med*. 2021;10(4).
4. Muntz A, Marasini S, Wang MTM, Craig JP. Prophylactic action of lipid and non-lipid tear supplements in adverse environmental conditions: A randomised crossover trial. *Ocul Surf*. 2020;18(4):920-925.